Telix Pharmaceuticals Ltd ADR TLX

Morningstar Rating
$8.97 +0.12 (1.30%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TLX is trading at a LOCK|^<BwZ premium.
Price
$8.85
Fair Value
LOCK|.DQD&>
Uncertainty
LOCK|>D&
1-Star Price
LOCK|.R$Zh$@
5-Star Price
LOCK|%jQBXm
Economic Moat
LOCK|#X
Capital Allocation
—

News

Trading Information

Previous Close Price
$8.86
Day Range
$8.91–9.05
52-Week Range
$6.29–13.09
Bid/Ask
$8.98 / $9.00
Shares Outstanding
339.78M
Market Cap
$3.04B
Volume/Avg
205,670 / 346,000

Key Statistics

Price/Earnings (Normalized)
77.86
Price/Sales
3.26
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
1,184

Competitors

Valuation

Metric
TLX
VRTX
REGN
Price/Earnings (Normalized)
77.8629.4218.84
Price/Book Value
8.206.482.96
Price/Sales
3.2610.556.05
Price/Cash Flow
—29.3517.48
Price/Earnings
TLX
VRTX
REGN

Financial Strength

Metric
TLX
VRTX
REGN
Quick Ratio
1.741.722.72
Current Ratio
2.012.343.35
Interest Coverage
1.5694.80106.89
Quick Ratio
TLX
VRTX
REGN

Profitability

Metric
TLX
VRTX
REGN
Return on Assets (Normalized)
2.08%17.70%14.40%
Return on Equity (Normalized)
6.42%25.16%18.83%
Return on Invested Capital (Normalized)
5.73%20.26%15.64%
Return on Assets
TLX
VRTX
REGN

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|CFD?R>bLOCK|kKr^Y$135B
Regeneron Pharmaceuticals Inc
REGN
LOCK|!F$dJtNLOCK|>%ldj$99B
Moderna Inc
MRNA
LOCK|@Ct^$@^LOCK|ln$84B
argenx SE ADR
ARGX
LOCK|#&<YzLLOCK|h#d$59B
BeOne Medicines Ltd ADR
ONC
LOCK|MF>%t%^LOCK|$#N$48B
Royalty Pharma PLC Class A
RPRX
LOCK|Z>#F>RjKLOCK|^q!PD$31B
Incyte Corp
INCY
LOCK|dCfc%^KLOCK|Cl#$24B
BioNTech SE ADR
BNTX
LOCK|yfP!pk#LOCK|>q$21B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|^Pnv!<LOCK|pntF&$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|pzG!!bLOCK|d!$15B

Sponsor Center